Skip to main content
. 2017 Mar 1;7(3):473–483.

Figure 4.

Figure 4

LY2606368 can sensitize the anticancer effect of PARP inhibitor BMN673 in gastric cancer cells. A, B. Graphical presentation of relative (%) cell viability of AGS and MKN1 cells after treatment with indicated drugs for 5 days. Cell viability was detected by MTS assays, significant synergistic anticancer effect between LY2606368 and BMN673 was observed in AGS and MKN1 cell, CI value of EC50 is 0.76 in AGS, and 0.41 in MKN1 (CI<1 indicates synergy). C. Clonogenic assay showed that LY2606368 (5 nM) and BMN673 (10 nM) combination inhibits cell survival of AGS and MKN1 cells. D. Graphical presentation of relative (%) colony formation in clonogenic assay as described in C (*P<0.05). E. Graphical presentation of (%) rate of apoptosis in AGS and MKN1 cells after treatment with 5 nM LY2606368, 1 µM BMN673, or both (AGS for 72 hours, MKN1 for 48 h) (*P<0.05). F. Western blot analyses of AGS and MKN1 cells treated with LY2606368, BMN673, or both. Combination of BMN673 and LY2606368 can induce more expression of apoptosis marker cleaved caspase3.